SBFM

Sunshine Biopharma, Inc. (SBFM) SWOT Analysis Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.8 (Weak)

Liquidity metrics are strong versus distressed microcap peers, but negative ROIC and a 148.6-day cash conversion cycle indicate capital is not being deployed efficiently.

A low debt-to-equity ratio suggests limited balance-sheet leverage versus more indebted peers, yet it does not offset the company’s weak operating return profile.

Current and quick ratios are well above minimum thresholds, which supports near-term solvency relative to peers, although this is a defensive rather than competitive advantage.

Weaknesses

Score:

Negative ROIC shows the business is destroying invested capital, leaving it structurally behind peers that at least earn positive returns on capital.

A 148.6-day cash conversion cycle ties up working capital for longer than healthier peers, which weakens liquidity efficiency and operating flexibility.

The absence of reported operating and gross margins limits evidence of durable unit economics, while peers with disclosed positive margins appear structurally stronger.

Low leverage does not translate into strength because the company’s capital structure still supports a weak earnings base, unlike peers with scalable profitability.

Opportunities

Score:

If working capital discipline improves, the long cash conversion cycle could shorten materially, creating more room for peers to outperform on cash efficiency.

A low debt burden leaves some balance-sheet capacity for operational restructuring, which could matter more than for highly levered peers.

Because current liquidity is ample, management has more near-term flexibility than tighter-liquidity peers to absorb execution delays while pursuing turnaround actions.

Threats

Score:

Persistent negative ROIC increases the risk that peers with positive returns compound value faster, widening the structural gap in investor capital allocation.

A prolonged cash conversion cycle can force continued working-capital absorption, leaving the company more exposed than peers with faster cash generation.

If operating performance remains weak, the company’s liquidity cushion may erode over time despite current ratios that look stronger than many peers.

Limited margin disclosure and weak profitability signal a fragile competitive position, especially versus peers that can reinvest internally at higher returns.

Overall Score

Score:

SBFM’s structural positioning is weak versus peers because liquidity is adequate, but negative capital returns and inefficient cash conversion dominate the competitive profile.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sunshine Biopharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →